Breast cancer is immunogenic, and infiltrating immune cells in primary breast tumors convey
important clinical prognostic and predictive information. Furthermore, the immune system is …

There is substantial need for molecularly defined tumor antigens to prime cytotoxic T cells in
vivo for cancer immunotherapy, especially in the case of tumor entities for which only a few …

PURPOSE: The HER-2/neu protein is a nonmutated tumor antigen that is overexpressed in
a variety of human malignancies, including breast and ovarian cancer. Many tumor antigens …

Tumor-specific CD8+ T cells can potentially be activated by two distinct mechanisms of
major histocompatibility complex class I–restricted antigen presentation as follows: direct …

The immune system is active in breast cancer, playing a dual role in tumor progression and
in immune surveillance. Infiltrating immune cells are both prognostic and predictive of …

Oral cancer is a global health burden with significantly poor survival, especially when the
diagnosis is at its late stage. Despite advances in current treatment modalities, there has …

Telomerase reverse transcriptase (hTERT) represents an attractive target for cancer
immunotherapy because hTERT is reactivated in most human tumors. A clinical trial was …

Patients with glioblastoma multiforme (GBM) are profoundly immunosuppressed and may
benefit from restoration of an antitumor immune response in combination with conventional …

Purpose Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting tumor
vaccines have demonstrated bioactivity but may be limited by disease burdens and immune …

Purpose: E75 is an immunogenic peptide from the HER2/neu protein, which is
overexpressed in many breast cancer patients. We have conducted two overlapping E75 …